Navigation Links
Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth

Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.'s expectations regarding the Company's strategic direction, prospects and future results, which statements are indicated by the words "will," "plan," "expect" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the successful marketing of CRINONE(R) 8% (progesterone gel), PROCHIEVE(R) 8%(progesterone gel), PROCHIEVE 4% (progesterone gel), and STRIANT(R) (testosterone buccal tablet) in the U.S.; the timely and successful development of new products, including the clinical and regulatory path for possible development of PROCHIEVE 8% for the prevention of preterm birth; the timely and successful completion of clinical studies; the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.

CRINONE(R), PROCHIEVE(R) and STRIANT(R) are registered trademarks of Columbia Laboratories, Inc.

Contact

Columbia Laboratories, Inc.
James A. Meer, 973-486-8860
Senior Vice President, CFO & Treasurer
or
Rx Communications, LLC
Melody A. Carey, 917-322-2571
Co-President


'"/>




Page: 1 2 3

Related medicine technology :

1. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
2. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
5. Northfield Laboratories Investor Update
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NYSE: RMD ) today announced changes ... his position as Chief Executive Officer and President, and ... has appointed Dr. Peter C. Farrell, ResMed,s founder and ... and President, effective January 28, 2011.  Dr. Farrell will ...
... CardioGenics Holdings Inc. (OTC Bulletin Board: ... Merck Chimie SAS continue the commercialization process of ... while it is refining its encapsulation of the ... of magnetic beads coated with CardioGenics, proprietary silver-coating ...
Cached Medicine Technology:ResMed Inc. Announces Management Changes 2ResMed Inc. Announces Management Changes 3CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 2CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 3
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/9/2014)... the Keck School of Medicine of the University ... lacking a specific component of the immune system ... complication of infection. The discovery suggests that blocking ... in human autoimmune and hyper-inflammatory diseases such as ... study was published online on June 23 in ...
(Date:7/8/2014)... Memory Restoration has been awarded up to $15 million ... a four -year project aiming to help brain-injured people ... in neurosurgery, engineering, neurobiology, psychology and physics will collaborate ... in the brain. , Memory is the process in ... information, store it and retrieve it. Certain types of ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
(Date:7/8/2014)... 2014 In a study published yesterday in the ... La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify ... currently affects over 200 million people world wide. , ... be divided into small sections or ,neighborhoods., Scientists can ... primed for gene production, by looking for a marker on ...
Breaking Medicine News(10 mins):Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... INDIANAPOLIS and MINNEAPOLIS, Aug. 19 WellPoint, Inc. (NYSE: ... RedBr i ck Hea l th ... entered into a strategic collaboration to create a new, behavior-based wellness ... health plan customers. , , Through an upcoming ...
... , WINSTON-SALEM, N.C., Aug. 19 A ... red blood cells, is now broadly available for the first time ... While scientists have long known of the benefits of fish and ... has proven that the omega-3 fatty acids found in fish dramatically ...
... , MURRIETA, Calif., Aug. 19 Forterus Inc. (Pink ... alcohol rehabilitation and other behavioral healthcare services, announced today revenues increased ... ended June 30, 2009 compared to revenues of $1.04 million, or ... , Forterus announced net income of $32,921, or $0.002 ...
... , LANHAM, Md., Aug. 19 ... immunization awareness campaign, Protecting our Future: The COSHAR Foundation ... new materials, including updated information about autism and vaccines and ... now. , , Through this ...
... modern drug, but not the most common, experts say, , ... remedy called "thunder god vine" helps reduce inflammation in people ... is an extract of the medicinal plant Tripterygium wilfordii ... gong teng" -- and has been used for centuries to ...
... , , NASHVILLE, ... managed care market intelligence, reports that while commercial pharmacy ... July 2008 and January 2009, commercial pharmacy benefit enrollment ... only a two percent decline over the same time ...
Cached Medicine News:Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 2Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 3Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 4Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 2Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 3Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 4Health News:Forterus Inc. Posts Revenue, Net Income Gains 2Health News:COSHAR Foundation Enhances National Childhood Immunization Awareness Campaign 2Health News:Herb Shows Potential for Rheumatoid Arthritis 2Health News:Herb Shows Potential for Rheumatoid Arthritis 3Health News:Miami-Area Experienced Fewer Fluctuations in Pharmacy Benefit Enrollment Than Other Florida Markets 2
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: